Combination therapy may help patients with follicular lymphoma

June 9, 2014
The data show that tumor growth halted in mice treated with a combination therapy (purple) using BCL2 (red) and CDK (green) inhibitors, in contrast to mice treated with individual inhibitors and compared with a control group (blue). Credit: Oricchio et al., 2014

A new study in The Journal of Experimental Medicine reveals that a high-risk group of patients with follicular lymphoma could benefit from a novel drug combination.

Follicular lymphoma, a B cell lymphoma, is an incurable form of non-Hodgkin lymphoma that is diagnosed each year in 120,000 people worldwide. Follicular lymphoma is characterized by slow and relentless tumor growth with inevitable relapses despite intense chemotherapy. Follicular lymphomas are driven by that activate the BCL2 protein, which prevents cancer cells from dying, but additional genetic changes are also required. These could include mutations resulting in loss of cell cycle control, which is a hallmark of cancer and has a well-established role in aggressive B cell malignancies.

To find out more, Hans-Guido Wendel and colleagues from Memorial Sloan-Kettering Cancer Center in New York analyzed genomic data from two large groups of slow-growing follicular lymphomas. The team identified a pattern of linked mainly in genes expressing cyclin-dependent kinases (CDKs), which impair the tumor-suppressing retinoblastoma (RB) pathway in nearly 50 percent of follicular lymphomas.

The pathogenic role of these mutations was also confirmed in vivo in a mouse model of follicular lymphoma. Increased CDK4 activity is readily measured in tumor samples, and Wendel and colleagues show that a combination therapy of CDK4 and BCL2 inhibitors is safe and effective against available mouse models of .

Explore further: Genetic profiling tracks progression from manageable blood cancer into deadly disease

More information: Oricchio, E., et al. 2014. J. Exp. Med. DOI: 10.1084/jem.20132120

Related Stories

Genetic profiling tracks progression from manageable blood cancer into deadly disease

December 23, 2013
Genetic profiling has painted the clearest picture yet of how a type of blood cancer – follicular lymphoma – develops and changes from a manageable disease into an aggressive cancer, offering new targets for treatment, ...

Inhibition of CDK4 might promote lymphoma development, progression

March 20, 2014
Anticancer agents that inhibit tumor growth by targeting a regulatory protein called CDK4 might actually promote the development and progression of certain B-cell lymphomas, according to a new study led by researchers at ...

Cancer: Lymphoma-linked risk factor identified

September 25, 2013
Follicular lymphoma is often caused by a translocation between chromosomes 14 and 18, resulting in the overexpression of a cancer-causing gene called BCL-2. A research team co-led by A*STAR scientists recently revealed another ...

Study of two sisters sheds light on lymphoma evolution

December 12, 2011
When a 41-year-old woman was diagnosed with chronic-phase chronic myeloid leukemia, she received a bone marrow transplant and subsequent leukocyte infusion from her sister. These treatments controlled her leukemia, but seven ...

Watch-and-wait OK in low-tumor burden follicular lymphoma

September 26, 2012
(HealthDay)—An initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure (FFTF) or overall survival rate in selected patients with low-tumor burden follicular lymphoma compared ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.